Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects-Reference-Cited by-同舟云学术

Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects

Author:

Deng Shaohui¹^ORCID,Li Xiaoxia¹,Liu Shuang¹²^ORCID,Chen Jifeng¹,Li Mingqiang³^ORCID,Chew Sing Yian⁴⁵^ORCID,Leong Kam W.⁶^ORCID,Cheng Du¹^ORCID

Affiliation:

1. PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou 510275, P.R. China.

2. Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510275, P.R. China.

3. Laboratory of Biomaterials and Translational Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, P.R. China.

4. School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore 637459, Singapore.

5. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore.

6. Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.

Abstract

Codelivery of CRISPR-Cas9 and chlorin e6 achieved spatially controlled tumor-specific gene editing with synergistic drug effects.

Funder

the National Natural Science Foundation of China

the National Key R&D Program of China

the Guangdong-Hongkong Joint Innovation Project

the Major Project on the Integration of Industry, Education and Research of Guangzhou City

the Guangdong Province Science and Technology Innovation Special Fund

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference40 articles.

1. A systematic analysis of FDA-approved anticancer drugs;Sun J.;BMC Syst. Biol.,2017

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献